Strides Shasun is currently trading at Rs. 965.50, up by 0.50 points or 0.05% from its previous closing of Rs. 965.00 on the BSE.
The scrip opened at Rs. 975.00 and has touched a high and low of Rs. 980.80 and Rs. 958.60 respectively. So far 75638 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1412.45 on 23-Nov-2015 and a 52 week low of Rs. 848.00 on 29-Feb-2016.
Last one week high and low of the scrip stood at Rs. 1052.45 and Rs. 948.20 respectively. The current market cap of the company is Rs. 8629.63 crore.
The promoters holding in the company stood at 31.14%, while Institutions and Non-Institutions held 47.98% and 20.89% respectively.
Strides Shasun has received an approval from the United States Food & Drug Administration (USFDA) for Polyethylene Glycol 3350, Powder for Solution 17 grams/capful and 17 grams/packet (OTC). The US market for Polyethylene Glycol 3350, Powder for Solution (OTC) is approximately USD 260 Million.
The product will be manufactured at company's flagship plant at Bangalore and will be marketed by Strides Pharma Inc in the US Market. The product will be launched in Q4 FY 2017, in line with the OTC procurement cycle in the market. Polyethylene glycol-3350 powder for oral solution is an osmotic laxative that relieves occasional constipation. It works by softening the stool and increasing the frequency of bowel movements by retaining water in the stool.
Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: